A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NCT05498428)
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Who can join: Review the eligibility criteria below.
Location: University of California at San Diego — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (110 Sites)
Showing the first 25 of 110 sites.
- University of California at San Diego — La Jolla, California
- University of California Irvine — Orange, California
- Stanford Cancer Institute — Stanford, California
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital — Washington D.C., District of Columbia
- Baptist Lynn Cancer Institute — Boca Raton, Florida
- Mount Sinai Medical Center — Miami Beach, Florida
- AdventHealth — Orlando, Florida
- H. Lee Moffitt Cancer & Research Institute — Tampa, Florida
- University of Kansas Cancer Center — Westwood, Kansas
- Sidney Kimmel Cancer Center - Bayview Campus — Baltimore, Maryland
- Boston Medical Center — Boston, Massachusetts
- Washington University School Of Medicine — St Louis, Missouri
- Hackensack University Medical Center — Hackensack, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Hematology-Oncology Associates of CNY — East Syracuse, New York
- Novant Health 1 — Charlotte, North Carolina
- Novant Health — Winston-Salem, North Carolina
- Cleveland Clinic 1 — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Cleveland Clinic 2 — Mayfield Heights, Ohio
- Cleveland Clinic 3 — Warrensville Heights, Ohio
- The Huntsman Cancer Institute — Salt Lake City, Utah
- Virginia Cancer Specialists — Fairfax, Virginia
- Providence Regional Cancer Partnership — Everett, Washington
- Virginia Mason Medical Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-small-Cell Lung
- MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California
Explore by condition: All Carcinoma, Non-small-Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.